Publications by authors named "Zhekun Xiong"
Cimifugin improves intestinal barrier dysfunction by upregulating SIRT1 to regulate the NRF2/HO-1 signaling pathway.
Naunyn Schmiedebergs Arch Pharmacol
September 2024
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal dysfunction. Cimifugin is an active component of Radix saposhnikoviae which is effective for maintaining intestinal barrier integrity and intestinal function. This study aimed to investigate the treatment efficacy of Cimifugin on intestinal barrier dysfunction and to unveil the relevant mechanism through network pharmacology and experimental verification as well as molecular docking.
View Article and Find Full Text PDFBackground: Currently, the effectiveness of TACE, Lenvatinib, and PD-1/L1 inhibitors used alone or in combination has been thoroughly reported. However, the differences in effectiveness between these treatment protocols require further verification. To this end, this study employs a Bayesian network meta-analysis to compare the efficacy and safety of TACE, Lenvatinib, and PD-1/L1 inhibitors, whether administered by monotherapy or in combination, providing evidence-based medicine for the treatment of unresectable HCC.
View Article and Find Full Text PDFArticle Synopsis
- MASLD (Metabolic dysfunction-associated steatotic liver disease) is on the rise due to obesity and lifestyle changes, prompting research into the therapeutic effects of ursolic acid, a natural compound.
- The study utilized various methods, including drug target chips and molecular docking, to explore ursolic acid's effects on MASLD and validated findings using animal models and isolated CD4+ T cells.
- Results showed that ursolic acid inhibits the inflammatory role of the protein SPP1 in Th17 cell differentiation, modulating immune responses through the ERK signaling pathway, highlighting its potential as a treatment for MASLD.